Table 1: Clinical information pertaining to samples tested.
| Patient Number | Clinical information | Age | Prior treatment | Interval post CTX (days) | Circulating blasts |
| 001 - sample 1 | M1 (FLT3 ITD-) | 42 | Nil | No CTX | Yes |
| 001 - sample 2 | DA × 1 | 17 | No | ||
| 001 - sample 3 | DA × 1 FLAG IDA × 2 | 42 | No* | ||
| 002 - sample 1 | M1 (FLT3 ITD+ NPM+) | 19 | Nil | No CTX | Yes |
| 002 - sample 2 | DA × 1 | 21 | No | ||
| 003 - sample 1 | Transformed from JAK2 mutant myeloproliferative disorder | N/A | FLA × 1 | 0 | No |
| 003 - sample 2 | FLA × 1 | 26 | Yes | ||
| 004 - sample 1 | M4 (Inv16) | 23 | HU | 0 | No |
| 004 - sample 2 | HU + DA × 1 | 26 | No | ||
| 005 - sample 1 | Transformed from refractory anemia with excess blasts with Inv (3)(q21q26) | N/A | DA | 46 | No |
| 005 - sample 2 | DA × 2 | 15 | No | ||
| 006 | M1 FLT3 ITD+ | 41 | DA × 1 | 28 | No |
| 007 - sample 1 | M1 FLT3 ITD+ | 56 | DA × 1 | 25 | No |
| 007 - sample 2 | DA × 2 | 28 | No | ||
| 008 | M4 t(6;11)(q27;q23) | 22 | DA × 1 | 28 | No |
| 009 | Transformed from JAK2 mutant myeloproliferative disorder; trisomy 8 | 57 | Nil | No CTX | Yes |
| 010 | N/A | N/A | Nil | No CTX | Yes |
CTX - chemotherapy; DA - daunorubicin + cytarabine; FLA - fludarabine + cytarabine; FLAG-IDA - fludarabine, cytarabine, G-CSF, idarubicin; HU - hydroxyurea; N/A - not available;
*Absolute lymphocyte count 0.2 × 109/L with no CD3+ cells detectable. Consequently, no expansion of γδ T-cells was observed from this sample.